Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents
NCT ID: NCT04966299
Last Updated: 2025-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2021-08-18
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
EryClot-Pilot:
Erythritol is also produced by the human body and possibly elevated erythritol levels in the blood are an indication of an increased risk of cardiovascular disease, obesity or diabetes in the future.
In a recently published study, a possible effect of erythritol on blood clotting function was described. In this in vitro experiment, increased blood clotting was observed when erythritol was added to clotting cells (platelets) in the test tube. Studies in humans on blood coagulation after administration of erythritol are missing so far.
With a pilot study, the investigators study whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood coagulation function after administration of erythritol will be investigated.
These preliminary tests serve to clarify the data situation so that further studies can be based on them.
The preliminary results of the EryClot\_Pilot study indicate that there appears to be no measurable effect of erythritol on thrombocyte aggregation. This implicates that there is a discrepancy between our results and the results reported in a recent published study. This is why we need to assess the effects of erythritol administration on more parameters of blood coagulation as well as in more subjects.
Due to a study published in June 2024, there appears the need to investigate the effects of xylitol on blood clotting function as well.
EryClot in vitro:
In addition to the human EryClot study, we will conduct in vitro experiments (aggregometry assay after addition of erythritol or xylitol in human platelet rich plasma).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Oral Xylitol on Subsequent Energy Intake
NCT05671965
Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers
NCT02821923
Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers
NCT02824614
Effects of Oral Pre-loads on Subsequent Energy Intake
NCT04713137
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents
NCT02499705
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
EryClot-Pilot:
The aim of this pilot study is to investigate whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood clotting function after administration of erythritol will be investigated.
EryClot:
The aim of this study is to investigate the erythritol level in blood after administration of erythritol and a possible effect on blood clotting function. Additionally, a possible effect of xylitol on blood clotting function will be investigated.
EryClot in vitro:
The aim of this study is to investigate the platelet responsiveness in vitro in human plasma after addition of erythritol and xylitol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
This trial is a randomized, double-blind, crossover trial. The project set-up is single-center, national. In total, 3 volunteers will be enrolled. There will be 3 study arms.
EryClot This trial is a randomized single-blind, crossover trial. The project setup is single-center national. In total 10 volunteers will be enrolled. There will be 3 study arms.
EryClot in vitro This trial is an in vitro trial using human blood samples. The project setup is single-center national. In total blood samples from 12 volunteers will be collected.
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sucrose
15 participants receive 25g sucrose per day during 5 weeks
Sucrose
Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
Erythritol
15 participants receive 36g eryhtritol per day during 5 weeks
Eryhtritol
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks
EryClot-Pilot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot-Pilot Erythritol
3 participants receive 50g erythritol dissolved in 300mL water once during the visit
Eryhtritol
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks
EryClot-Pilot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot-Pilot Glucose
3 participants receive 75g glucose dissolved in 300mL water once during the visit
Glucose
Glucose 75g dissolved in 300mL water administered once per visit
EryClot-Pilot Fructose
3 participants receive 25g fructose dissolved in 300mL water once during the visit
Fructose
Fructose 25g dissolved in 300mL water administered once per visit
EryClot Erythritol
10 participants receive 50g erythritol dissolved in 300mL water once during the visit
Eryhtritol
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks
EryClot-Pilot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot Xylitol
10 participants receive 33.5g xylitol dissolved in 300mL water once during the visit
Xylitol
Xylitol 33.5g dissolved in 300mL water administered once per visit
EryClot Water
10 participants receive 300mL water once during the visit
Water
300mL water administered once per visit
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eryhtritol
Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks
EryClot-Pilot:
Erythritol 50g dissolved in 300mL water administered once per visit
EryClot:
Erythritol 50g dissolved in 300mL water administered once per visit
Sucrose
Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
Glucose
Glucose 75g dissolved in 300mL water administered once per visit
Fructose
Fructose 25g dissolved in 300mL water administered once per visit
Xylitol
Xylitol 33.5g dissolved in 300mL water administered once per visit
Water
300mL water administered once per visit
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 14-18 years
* Normal weight (BMI between 15th and 85th percentile for age and gender)
* Minimum weight of 45kg
* Regular sugar consumption \>25g/d
* Healthy participants 18-55 years upon inclusion
* Normal weight (BMI between 19.0-24.9 kg/m2)
* Informed consent signed by participant
* Healthy participants 18-55 years upon inclusion
* Normal weight (BMI between 19.0-24.9 kg/m2)
* Informed consent signed by participant,
* Healthy participants 18-55 years upon inclusion
* BMI \< 30 kg/m2
* Informed consent signed by participant
Exclusion Criteria
* Pregnancy
* Regular intake of prebiotics
* Regular intake of probiotics
* Regular intake of pro-/prebiotic foods
* Antibiotics cure within 3 months preceding the present study
* Substance abuse
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol
* Fructose-intolerance
* Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.)
EryClot-Pilot:
3 participants
* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol
* Fructose-intolerance
EryClot:
* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol or xylitol
* Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.))
EryClot in vitro
* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded.
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol or xylitol
* Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.))
14 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bettina K. Wölnerhanssen, PD. MD
Role: PRINCIPAL_INVESTIGATOR
St. Clara Research Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Claraspital
Basel, Canton of Basel-City, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EryAdo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.